IL6 and rheumatoid arthritis: In addition to a marked and rapid reduction in levels of human serum CRP in adult RA patients previously described (Tanaka et al, 2016), baricitinib treatment also reduced the mean change from baseline of plasma IL‐6 in adult RA patients.